SEATTLE, Aug. 2, 2018 /PRNewswire/ -- Mindshare Medical announced today that its RevealAI-Lung product has been approvedby Health Canada for use with CT lung cancer screening nationwide.
The product, a Computer Assisted Diagnostic (CADx) software for lung cancer diagnosis, is the first diagnostic platform to gain regulatory
Mindshare has demonstrated the potential for reducing both false-positives and time to diagnosis, alleviating patient exposure to unnecessary imaging and biopsy risks, while providing the opportunity to treat lung cancer at an earlier stage.
"I've been a proponent of further personalizing the decision about how aggressively to follow up a lung nodule based on many additional parameters specific to that lung nodule including shape, texture, location, and change over time. I think that more granular, precision based approaches will allow us to screen more efficiently and make more relevant recommendations for care for a specific patient. This radiomics-based approach will become increasingly utilized in the next several years," said Dr. Eliot Siegel, Professor of Diagnostic Radiology for the University of Maryland Medical Center in Baltimore, USA.
According to the Canadian Cancer Society, lung cancer is the leading cause of death among men and women in the country, representing 14% of all newly diagnosed cancers in 2017 and an average of 58 deaths each day, with 1 in 12 people in Canada developing lung cancer at some point in their lifetime.
Taking into account Canada's 5-year net survival rate of 17%, the ability to intercept and treat a malignant nodule even a few months earlier could yield significant benefit to patients. In addition to these clinical advantages, when considering the financial burden to the healthcare system, reducing the unnecessary procedures from false-positives yields substantial cost-savings. Mindshare's RevealAI can play a key role in the adoption of value-based health care.
In current practice, people regarded as 'high risk' for lung cancer (aged 50-74 and 30 pack years) might undergo a Low Dose CT (LDCT). If a suspicious nodule is found, current guidelines place patients in a few categories for follow-up based on a limited set of characteristics. This results in unnecessary follow-up imaging, biopsies and surgeries on people who don't have lung cancer.
Mindshare's technology uses a radiomics approach. The analytics generate a Malignancy Similarity Index (mSI) composed of hundreds of characteristics from the CT (out of thousands examined), combined into a morphological biomarker of malignancy. This biomarker is used to compare the nodule being diagnosed with nodules in the company's reference database that have known diagnostics and outcomes. This provides the physician with not only a raw numerical malignancy score for the nodule, but places it within a population context. The result is improved targeted follow-up for patients that need it and greater confidence in giving the 'all-clear' for patients that don't.
"We've seen how genomics can really help target follow-up and therapy for cancers. This approach applied to radiology has the same goal - while reducing overall healthcare costs. Mindshare takes advantage of widely-used screening modalities and increases efficacy in today's clinical workflow. We aim to get this in clinicians' hands as fast as possible to improve patient outcomes at national scale."Michael Calhoun, PhD. CEO, Mindshare Medical
Mindshare Medical develops revolutionary, evidence-based clinical decision support technologies that provide personalized diagnostics and guidance on the effectiveness of follow-up procedures and treatments. This precision medicine radiomics approach is intended to dramatically optimize patient outcomes and reduce the financial burden for health care organizations. Mindshare's solutions are designed to fit within the clinical workflow - delivering impactful insights at the clinician's fingertips.
Health Canada, part of the Health Portfolio, is responsible for helping Canadians maintain and improve their health. It ensures that high-quality health services are accessible, and works to reduce health risks.
View original content:http://www.prnewswire.com/news-releases/mindshare-medical-announces-health-canada-clearance-for-nationwide-use-of-revealai-lung-product-300690735.html
SOURCE Mindshare Medical
Subscribe to our Free Newsletters!
Osteolysis refers to breaking down of bone tissue. Bone loss occurs due to resorption of bone by ...
Patisiran injection, recently approved by FDA to treat polyneuropathy, a disease that causes ...
Dysgraphia or disorder of written expression is a childhood learning disorder marked by poor ...View All